To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Directorate Changes

Release Date: 24/07/2019 15:50
Code(s): MEI     PDF:  
 
Wrap Text
Directorate Changes

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", or the "Company" or the "Group")

24 July 2019

DIRECTORATE CHANGES

APPOINTMENT OF TOM SINGER AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR

Mediclinic announces that Tom Singer is to join its Board as an independent non-executive director with
effect from 24 July 2019.

Dr Edwin Hertzog, Chairman of Mediclinic, commented:

"The Board is delighted to welcome Tom Singer as an independent non-executive director of the
Company. His financial acumen and expertise in UK listed international hospitality and branded
consumer businesses will be valuable additions to the Board’s existing skillset."

Tom has extensive board experience and expertise in international branded consumer businesses and
a thorough understanding of the UK listed environment. He has served as Chief Financial Officer of
InterContinental Hotels Group PLC, a leading international hotel group, and British United Provident
Association (BUPA), a provider of health insurance, care homes for the elderly and other health related
services including private hospitals. Earlier in his career, Tom was Chief Financial Officer and Chief
Operating Officer of William Hill PLC and Finance Director of Moss Bros PLC, having started his career
in professional services spending a total of 12 years at Price Waterhouse and McKinsey. He currently
serves as a non-executive director on the boards of DP Eurasia N.V., an operator of pizza restaurants
in Turkey and Russia, and Liberty Living Group PLC, a provider of student accommodation in the UK.

Tom holds a degree in Economics and Accounting (University of Bristol), is a Chartered Accountant and
has attended the Advanced Management Programme at INSEAD.

There are no disclosures required pursuant to paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing
Authority's Listing Rules in respect of this appointment. Tom Singer’s fees will amount to £73 000 per
annum, including the fee payable for membership of the Audit and Risk Committee as referred to below,
which is in line with current independent non-executive directors.

CHANGES TO COMMITTEE MEMBERSHIPS

The Board also agreed to certain other changes to the membership of its committees. As announced
on 15 November 2018, Desmond Smith, the Company’s Senior Independent Director, will be retiring as
a director of the Company upon the conclusion of the Company’s Annual General Meeting being held
today, at which point his memberships of all Board committees will cease. Alan Grieve will succeed
Desmond Smith as Senior Independent Director of the Company and as Chairman of the Audit and
Risk Committee. The Company also confirms the following Board committee changes:

Audit and Risk Committee:
With effect from 24 July 2019, Desmond Smith will step down as a member and Chairman of the Audit
and Risk Committee. Alan Grieve will succeed Desmond Smith as Chairman of this Committee and
Tom Singer will become a member of this committee from that date.

Nomination Committee:
With effect from 24 July 2019, Desmond Smith will step down as a member of the Nomination
Committee and will be succeeded on that committee by Alan Grieve.

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983,
with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab
Emirates.

The Group’s core purpose is to enhance the quality of life by way of appropriate healthcare services.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and trusted
provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare
in each of its markets.

Mediclinic comprises 77 hospitals, five sub-acute hospitals, 13 day case clinics and 21 outpatient
clinics. Hirslanden operates 18 hospitals, two day case clinics and three outpatient clinics in
Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates 52 hospitals,
five sub-acute hospitals and 9 day case clinics with more than 8 500 inpatient beds; and Mediclinic
Middle East operates seven hospitals, two day case clinics and 21 outpatient clinics with more than
900 inpatient beds in the United Arab Emirates.

The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with
secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE Ltd sponsor: Rand Merchant Bank (A division of FirstRand Bank Ltd)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 24/07/2019 03:50:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Email this JSE Sens Item to a Friend.

Share This Story